Ultragenyx Pharmaceutical Inc. Stock News

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2021 Results - Earnings Call Transcript

Ultragenyx Pharmaceutical press release (RARE): Q4 GAAP EPS of -$1.79 misses by $0.44.Revenue of $83.4M (-8.9% Y/Y) misses by $0.28M.The company expects 2022 revenue for Crysvita

2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories 1 of $192.6 million

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to announce Q4 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is -$1.19 (-221.6% Y/Y)…

NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 10, 2022, at 5:00 pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2021.

NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri

Ultragenyx Pharmaceutical (RARE) granted two newly hired non-executive officers non-qualified stock options to buy a total of 16.05K common shares and 5,350 restricted stock units

Ultragenyx Pharmaceutical Inc. (RARE) shares closed today at 1.5% above its 52 week low of $63.38, giving the company a market cap of $4B. The stock is currently down 19.0% year-to-date, down 51.3% over the past 12 months, and down 0.8% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 13.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 9.2% The company's stock price performance over the past 12 months beats the peer average by -0.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Biopharma weakened sharply in 2021, driven by the underperformance in SMIDs, a group of analysts from Morgan Stanley laments, noting a "show me" attitude among investors for next year

Regeneron Pharmaceuticals (REGN) and Ultragenyx Pharmaceutical (RARE) announce a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and

NOVATO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect Conference on Thursday, January 13, 2022 at 7:00 AM ET. The live and archived webcast of … Full story available on Benzinga.com

NOVATO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser